-
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver dise Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of...资讯2024-02-27
最热